Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma

Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The FGFR inhibitor BGJ398 displayed encouraging efficacy in patients with FGFR2 fusion-positive ICC in a phase II trial, but...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Goyal, Lipika, Saha, Supriya K., Liu, Leah Y., Siravegna, Giulia, Leshchiner, Ignaty, Ahronian, Leanne G., Lennerz, Jochen K., Vu, Phuong, Deshpande, Vikram, Kambadakone, Avinash, Mussolin, Benedetta, Reyes, Stephanie, Henderson, Laura, Sun, Jiaoyuan Elisabeth, Van Seventer, Emily E., Gurski, Joseph M., Baltschukat, Sabrina, Schacher-Engstler, Barbara, Barys, Louise, Stamm, Christelle, Furet, Pascal, Ryan, David P., Stone, James R., Iafrate, A. John, Getz, Gad, Porta, Diana Graus, Tiedt, Ralph, Bardelli, Alberto, Juric, Dejan, Corcoran, Ryan B., Bardeesy, Nabeel, Zhu, Andrew X.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5433349/
https://ncbi.nlm.nih.gov/pubmed/28034880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1000
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados